- Did you mean
- comparable
Search results - 8 results
Interim analysis of COVID-19 vaccine effectiveness against hospitalisation and death using electronic health records in six European countries
period covered in this report is April 2022 to March 2023. The rVE of first, second and third booster doses was estimated and compared to the VE of complete primary vaccination received at least 24 weeks ...
Factors underlying COVID-19 booster vaccine uptake among adults in Belgium
variables. Among adults, there was generally a higher uptake to receive the first booster among older age groups compared to younger ones. Females, individuals residing in Flanders and those with no previous ...
Vaccine effectiveness of the second and third COVID-19 boosters in Belgium (administered during 2022 autumn campaign)
following the autumn vaccination campaign of 2022, compared to those who did not receive a vaccine during this time. Health Topics: Vaccin Vaccin Vaccin Service: Épidémiologie des maladies infectieuses ...
Round table discussion on posters: comparability and testing challenges
Countries,, PDA Europe, Issue PDA Europe, Berlin, Germany (2015) Keywords: challenge CHALLENGES COMPARABILITY conference Countries developing Developing Countries Discussion Europe ON TESTING vaccine vaccines ...
Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting.
DNA-primed-protein-boosted animals, compared to those that received only the DNA vaccination. Moreover, these responses appeared to be better sustained over time. Antibodies were readily produced by all three methods of ...
Tuberculosis DNA vaccine encoding Ag85A is immunogenic and protective when administered by intramuscular needle injection but not by epidermal gene gun bombardment.
a DNA vaccine encoding Ag85A from Mycobacterium tuberculosis were compared in BALB /c and C57BL (B6 and B10) mice immunized by intramuscular (i.m.) needle injection or epidermal gene gun (gg) bombardment. ...
Immunogenicity and protective efficacy of DNA vaccines encoding secreted and non-secreted forms of Mycobacterium tuberculosis Ag85A.
DNA Abstract: OBJECTIVE: To determine the efficacy of Ag85A- DNA against challenge with a highly virulent human clinical isolate of Mycobacterium tuberculosis (CSU37) and to compare the potencies of two ...
Differences in Antigenic Structure of Inactivated Polio Vaccines Made From Sabin Live-Attenuated and Wild-Type Poliovirus Strains: Impact on Vaccine Potency Assays.
not been standardized, no international references exist, and no antigen units have been defined for a sIPV human dose. Thus, sIPV products from different manufacturers cannot be compared, and the ...